In the realm of pharmaceuticals, the question arises: are U.S. pharma companies prepared to shift their life science manufacturing operations back home? This query delves into the potential implications of such a move, considering factors like advancements in robotics for hazardous tasks and the development of hardware/software architectures inspired by autonomous driving technologies. While fully automated response systems are still a futuristic concept, laying the groundwork for this future is crucial as new facilities are constructed.
• The discussion revolves around the readiness of U.S. pharma companies to bring life science manufacturing operations back to domestic soil.
• Advancements in robotics, especially for hazardous tasks, are seen as key drivers in transforming manufacturing operations.
• Companies like NVIDIA are already adapting hardware/software architectures from autonomous driving technologies.
• The focus is on building new facilities that can support potential future automation in response systems.
Read more from forbes.com
